Original ResearchFull Report: Clinical—Alimentary TractRamosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women
-
Add time:08/29/2019 Source:sciencedirect.com
Background & AimsPrevious studies have indicated that serotonin-3–receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.
We also recommend Trading Suppliers and Manufacturers of Ramosetron hydrochloride (cas 132907-72-3). Pls Click Website Link as below: cas 132907-72-3 suppliers
Prev:Original articleAlimentary tractEffect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea
Next:Pulmonary, gastrointestinal and urogenital pharmacologyInhibitory effect of the selective serotonin 5-HT3 receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study09/04/2019
- Prophylactic Antiemetic Efficacy of Granisetron or Ramosetron in Patients Undergoing Thyroidectomy09/03/2019
- Full PaperInhibitory Effects of Ramosetron, a Potent and Selective 5-HT3–Receptor Antagonist, on Conditioned Fear Stress–Induced Abnormal Defecation and Normal Defecation in Rats: Comparative Studies With Antidiarrheal and Spasmolytic Agents09/02/2019
- Full PaperEvaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome09/01/2019
- Oral formulations of the selective serotonin3 antagonists ramosetron (intraoral disintegrator formulation) and granisetron hydrochloride (standard tablet) in treating acute chemotherapy-induced emesis, nausea, and anorexia: A multicenter, randomized, single-blind, crossover, comparison study08/31/2019
- Pulmonary, gastrointestinal and urogenital pharmacologyInhibitory effect of the selective serotonin 5-HT3 receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats08/30/2019
- Original articleAlimentary tractEffect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea08/28/2019
- Mucoadhesive suppositories of Ramosetron hydrochloride (cas 132907-72-3) utilizing Carbopol®08/27/2019
-
Health and Chemical more >